ImranChaudharyMD

PubMed

• 4 citations
  Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials
  Audrey E. Kam, Gopichand Pendurti, Umang Shah, M. H. Ghalib, Imran Chaudhary, Jennifer W. Chuy, Lakshmi Rajdev, Andreas Kaubisch, Santiago Aparo, Ioannis Mantzaris, Sa...> ;Investigational New Drugs. 2019 Jun 1
• 4 citations
  Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010
  June Y. Hou, Santiago Aparo, M. H. Ghalib, Imran Chaudhary, Umang Shah, Umang Swami, Mark H. Einstein, Gary L. Goldberg, Sridhar Mani, Sanjay Goel> ;Gynecologic Oncology. 2013 Oct 1
• 29 citations
  Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.
  Razelle Kurzrock, Sanjay Goel, Jennifer J. Wheler, David S. Hong, Siqing Fu, Keyvan Rezai, Sonia K. Morgan-Linnell, Saik Urien, Sridhar Mani, Imran Chaudhary, Mohammed...> ;Cancer. 2012 Dec 15
• 59 citations
  Eribulin—A review of preclinical and clinical studies
  Umang Swami, Imran Chaudhary, M. H. Ghalib, Sanjay Goel> ;Critical Reviews in Oncology/hematology. 2012 Feb 1
• A phase I study of the novel DNA topoisomerase-1 inhibitor, TLC388, administered intravenously to patients with advanced solid tumors.
  Ghamande SA, Lin C, Cho DC, Coleman TA, Chaudhary I, Cleary JM, Silverman MH, Kuo M, Mach W, Tseng Y, Hsu SC, Goel S> ;J. Clin. Oncol.. 2011-05-20
• Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors.
  Ohnuma T, Holland JF, Goel S, Wilck E, Lehrer D, Ghalib MH, Chaudhary I, Wilhelm F, Swami U, Mani S> ;J. Clin. Oncol.. 2011-05-20
• Risks and benefits of phase I trials: Twelve-years experience from a single institution.
  Swami U, Ghalib MH, Chaudhary I, Hou JY, Aparo S, Einstein MH, Goldberg GL, Elrafei TN, Gajavelli S, Cohen B, Rajdev L, Kaubisch A, Haigentz M, Mani S, Goel S> ;J. Clin. Oncol.. 2011-05-20
• 101 citations
  Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors
  Radharani Gollamudi, M. H. Ghalib, Kavita K. Desai, Imran Chaudhary, Benny Wong, Mark H. Einstein, Matthew C. Coffey, George M. Gill, K. Mettinger, John M. Mariadason,...> ;Investigational New Drugs. 2010 Oct 1
• Assessment of quality of life using FACT-G survey in a phase I trial in cancer patients.
  Jung G, Knight D, Moadel A, Desai K, Chaudhary I, Gajavelli S, Ghalib MH, Mani S, Goel S> ;J. Clin. Oncol.. 2009-05-20
• Dose escalation and pharmacodynamic study of intravenous adminstration of Reolysin, a live replication competent RNA virus in patients with advanced solid tumors.
  Ghalib MH, Desai KK, Gollamudi R, Chaudhary I, Einstein M, Coffey M, Mettinger K, Mani S, Goel S> ;J. Clin. Oncol.. 2009-05-20
• 9 citations
  Alterations of chemotherapeutic pharmacokinetic profiles by drug–drug interactions
  Sridhar Mani, Mohammed Ghalib, Imran Chaudhary, Sanjay Goel> ;Expert Opinion on Drug Metabolism & Toxicology. 2009 Feb 24
• Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer.
  Vainshtein JM, Ghalib MH, Kumar M, Chaudhary I, Maniar M, Taft DR, Cosenza S, Reddy EP, Goel S, Mani S> ;J. Clin. Oncol.. 2008-05-20
• Clinical benefits and risks of phase I oncology trials: experience from a single institution.
  Gollamudi R, Wong BM, Ghalib MH, Kumar M, Desai K, Chaudhary I, Goel S, Mani S> ;J. Clin. Oncol.. 2008-05-20
• 6 citations
  Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers
  Sanjay Goel, K. Desai, Sirisha Karri, Radharani Gollamudi, Imran Chaudhary, Anca Bulgaru, Andreas Kaubisch, Gary L. Goldberg, Mark H. Einstein, Fernando Camacho, Shary...> ;Investigational New Drugs. 2007 Jun 1
• Effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone.
  Goel S, Goldberg G, Iacono LC, Cohen M, Griffin T, Gollamudi R, Desai KK, Chaudhary I, Mani S> ;J. Clin. Oncol.. 2006-06-20
• Pharmacokinetic (pk) and safety study of irinotecan (Ir) and capecitabine (Cp) administered on a weekly schedule.
  Gollamudi R, Baker SD, Desai KK, Chaudhary I, Kaubisch A, Camacho FJ, Einstein M, Goldberg G, Goel S, Mani S> ;J. Clin. Oncol.. 2006-06-20
• 6 citations
  Evolution in the practice of primary angioplasty: effect of adjunctive coronary stenting and glycoprotein IIb/IIIa inhibitors on long-term outcomes.
  Vijay G. Kalaria, Imran N. Chaudhary, Seth Jacobson, Richard M. Pomerantz, Christopher J. Cove, Frederick S. Ling, Donald E. Cutlip> ;Catheterization and Cardiovascular Interventions. 2001 Nov 1
• Join now to see all